CJC-1295 with DAC

What Is CJC‑1295 with DAC?

CJC‑1295 with DAC is a synthetic peptide analog of growth hormone–releasing hormone (GHRH), modified with a drug affinity complex (DAC) to extend its biological half‑life. Developed for investigational use, this formulation allows sustained stimulation of endogenous growth hormone secretion, distinguishing it from the shorter‑acting non‑DAC variant.

Mechanism of Action

CJC‑1295 with DAC binds to GHRH receptors on anterior pituitary somatotrophs, activating adenylate cyclase and calcium‑dependent signaling cascades. This receptor engagement promotes prolonged GH release, which in turn elevates circulating insulin‑like growth factor‑1 (IGF‑1). The DAC modification enables covalent binding to serum albumin, significantly extending peptide stability and duration of action. This pharmacokinetic profile supports continuous GH stimulation over days, reducing injection frequency while maintaining anabolic and metabolic effects.

Research & Clinical Data

CJC‑1295 with DAC remains investigational, with limited published human trial data. Preclinical and early clinical studies suggest potential benefits in lean tissue growth, lipid metabolism, recovery enhancement, and age‑related GH decline. Comparative analyses highlight its extended half‑life versus non‑DAC formulations, making it a candidate for sustained GH modulation. Regulatory approval for therapeutic use has not yet been established.

Purity & Quality

Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved.

Classification & Handling Class: GHRH analog | Modification: DAC | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: Investigational, non‑approved